AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02423317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation with Miller's blade
Description: Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
Study NCT02423317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation with Airtraq
Description: Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
Study NCT03722862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fiber
Description: Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses
Study NCT03722862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the placebo/dextrose.
Study NCT03722862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber
Description: Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
Study NCT03698487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
Study NCT01432028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol and Progesterone
Description: 3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
Study NCT01432028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol and Drospirenone
Description: oral estradiol 1mg and drospirenone 2 mg/day
Study NCT00003404 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy
Description: Adjuvant radiation therapy
Study NCT01128868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal femur locking plate
Description: Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
Study NCT01128868 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intertrochanteric nail
Description: Intertrochanteric nail (PFNA, TFN, GN)
Study NCT02400463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT00792207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Coach software
Description: The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
Study NCT00792207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor and website
Description: The control group will use an activity monitor and a website to track activity levels.
Study NCT00547547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-selenium Brassica juncea
Description: Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
Study NCT00547547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
Study NCT00547547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
Study NCT02701699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 18-F-FAZA
Description: All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
Study NCT02503410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
Study NCT02503410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive gaming
Description: Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
Study NCT04206800 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ejaculatory abstinence less than 24 hours
Description: Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
Study NCT03386474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: Administered as opthalmic solution for an intravitreal injection to the study eye
Study NCT03386474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept 2 mg
Description: Administered as an opthalmic solution for intravitreal injection to the study eye
Study NCT03051750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex Physical Therapy plus Pressotherapy
Study NCT03051750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Study NCT03824652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual diet
Description: Subject continues usual diet
Study NCT03002389 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anoro Ellipta
Description: inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
Study NCT03002389 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Arnuity Ellipta
Description: inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
Study NCT03824652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone counseling with dietitian
Description: Weekly calls with dietitian
Study NCT04264442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: Patients will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor. The study drug should be taken with food and the date and time of each dose taken should be recorded in the subject diary.
Study NCT02739334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENRICH
Description: The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
Study NCT02739334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - monthly handouts
Description: The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
Study NCT02284958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Back care advice
Study NCT02284958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Back care advice, individualized 12 week pedometer-driven walking program
Study NCT00392171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression
Study NCT00843297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coolgard
Description: invasive Cooling via femoral ICY-catheter
Study NCT00843297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArcticSun
Description: Noninvasive surface-cooling by saline-cooled thermo-vest
Study NCT00843297 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Intensive care-treatment without cooling
Study NCT02689219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Both cohorts will be treated similarly and in parallel but analyzed separately.
Study NCT00795847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preminent (losartan/hydrochlorothiazide combination drug)
Description: Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
Study NCT00795847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preminent (losartan/hydrochlorothiazide combination drug)
Description: Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
Study NCT03383458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03383458 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: specified dose on specified days
Study NCT03687112 — intervention group
Intervention type: OTHER
Intervention: non ontervention / observational study
Description: non intervention
Study NCT01596387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
Study NCT03081975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD white light or NBI
Description: Use of NBI or HD white light
Study NCT00066729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 peptide vaccine
Description: NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51
Study NCT05766098 — intervention group
Intervention type: GENETIC
Intervention: Genotyping
Description: Characterization of genetic profile of tumor tissues
Study NCT03529019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensure Surgery Immunonutrition Shake
Description: An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
Study NCT03529019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensure Enlive Advanced Nutrition Shake
Description: An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
Study NCT03340792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulation training utilizing an exoskeleton robot
Description: Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
Study NCT02114112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP cycling
Study NCT02114112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP continuous
Study NCT00925873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator (no fludarabine)
Description: 1. Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~2. The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~3. Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)
Study NCT00925873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental (fludarabine)
Description: The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2.
Study NCT03069417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrating Nuanced Support for Perinatal adherence and Depression
Description: A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
Study NCT03069417 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Integrating Nuanced Support for Perinatal adherence and Depression
Description: A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
Study NCT00527917 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: bladder instillation
Study NCT00527917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uracyst
Description: 20 ml sterile solution for weekly intravesical instillation
Study NCT02045524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep muscle injection
Study NCT02045524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-Q Injection
Study NCT04640012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC371739
Description: Participants received one of 6 dose levels of DC371739 administered as single oral doses.
Study NCT04640012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered
Study NCT01590251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
Study NCT01590251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Counseling
Description: One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
Study NCT02050035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
Study NCT04418531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients
Description: Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
Study NCT02247518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cialis Tab. 5mg
Study NCT02247518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Harnal-D Cap. 0.2mg
Study NCT00047047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00047047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00047047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00047047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01143831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K, 20mg
Description: Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
Study NCT00889252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contact lens with ketotifen
Description: K-Lens (generic name not established) and Ketotifen combination drug-device product
Study NCT00889252 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: contact lens
Description: Placebo contact lens
Study NCT01527838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single FT1050 treated UCB unit
Description: Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
Study NCT02941588 — intervention group
Intervention type: PROCEDURE
Intervention: Non-cardiac surgery
Description: Any surgery with general anesthesia except cardiac surgery
Study NCT05183711 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
Study NCT03474133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
Study NCT01166412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2
Description: 6.5mg patch daily for 11 weeks
Study NCT01166412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel patch with BMI <32 kg/m2
Description: 6.5mg patch daily for 11 weeks
Study NCT01166412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2
Description: 12.5mg patch daily for 11 weeks
Study NCT01166412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel patch with BMI <32 kg/m2
Description: 12.5mg patch daily for 11 weeks
Study NCT01595737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
Study NCT01595737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
Study NCT01905319 — intervention group
Intervention type: OTHER
Intervention: Blood collecting for storage of samples
Study NCT01975766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
Study NCT01975766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Study NCT02918487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyherbal
Description: Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
Study NCT02918487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyherbal
Description: Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
Study NCT02918487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive compound that is similar looking as the intervention
Study NCT02918487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive compound that is similar looking as the intervention
Study NCT00658372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
Study NCT03879447 — intervention group
Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
Study NCT03879447 — intervention group
Intervention type: PROCEDURE
Intervention: Chuna manual medicine
Description: Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.